Shift From Adalimumab Originator to Biosimilars in Denmark

Abstract

The dashed horizontal line represents the Danish patent expiration of the brand-name adalimumab on October 16, 2018. The patent expiration was immediately followed by a shift to biosimilars with a substantial cost reduction.